Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 10/20 | 0.42 |
| ▸ | CDK2 | P24941 | 10/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 9/20 | 0.42 |
| ▸ | CDK1 | P06493 | 5/20 | 0.42 |
| ▸ | CDK4 | P11802 | 5/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.42 |
| ▸ | CCND1 | P24385 | 4/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadisegliatin SCHEMBL2648148 | 1.00 | CCNE1 (0.42) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2647886 | 1.00 | CCNE1 (0.42) | CCNE1CDK2CCNE2CDK1CDK4 | |
| Cadisegliatin SCHEMBL999940 | 1.00 | CCNE1 (0.42) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2647888 | 1.00 | CCNE1 (0.42) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2648870 | 0.99 | CDK2 (0.43) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2648871 | 0.99 | CDK2 (0.43) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2650481 | 0.94 | CCNE1 (0.44) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2650478 | 0.94 | CCNE1 (0.44) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2649344 | 0.94 | CCNE1 (0.44) | CCNE1CDK2CCNE2CDK1CDK4 | |
| SCHEMBL2649343 | 0.94 | CCNE1 (0.44) | CCNE1CDK2CCNE2CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479808-B2 | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof | VTV THERAPEUTICS LLC (US) | 2025-11-25 | — | — | US | claimed |
| US-20250288681-A1 | SOLID COMPOSITIONS COMPRISING A GLUCOKINASE ACTIVATOR AND METHODS OF MAKING AND USING THE SAME | VTV THERAPEUTICS LLC | 2025-09-18 | — | — | US | claimed |
| EP-4487909-A2 | THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN OR INSULIN ANALOGS | vTv Therapeutics LLC (US) | 2025-01-08 | — | — | EP | claimed |
| US-20240245656-A1 | THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN OR INSULIN ANALOGS | VTV THERAPEUTICS LLC | 2024-07-25 | — | — | US | claimed |
| US-11974989-B2 | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs | VTV THERAPEUTICS LLC (US) | 2024-05-07 | — | — | US | claimed |
| US-11833136-B2 | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs | VTV THERAPEUTICS LLC (US) | 2023-12-05 | — | — | US | claimed |
| US-20230219909-A1 | SALTS OR CO-CRYSTALS OF {2-[3-CYCLOHEXYL-3-(TRANS-4-PROPOXY-CYCLOHEXYL)-UREIDO]-THIAZOL-5-YLSULFANYL}-ACETIC ACID AND USES THEREOF | VTV THERAPEUTICS LLC | 2023-07-13 | — | — | US | claimed |
| US-20230219910-A1 | CRYSTALLINE FORMS OF {2-[3-CYCLOHEXYL-3-(TRANS-4-PROPOXY-CYCLOHEXYL)-UREIDO]-THIAZOL-5-YLSULFANYL}-ACETIC ACID AND USES THEREOF | VTV THERAPEUTICS LLC | 2023-07-13 | — | — | US | claimed |
| CN-116194442-A | Salts or co-crystals of {2- [ 3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl) -ureido ] -thiazol-5-ylsulfanyl } -acetic acid and uses thereof | 维特卫治疗有限责任公司 | 2023-05-30 | — | — | CN | claimed |
| CN-116056760-A | Crystalline forms of {2- [ 3-cyclohexyl-3- (trans-4-propoxy-cyclohexyl) -ureido ] -thiazol-5-ylsulfanyl } -acetic acid and uses thereof | 维特卫治疗有限责任公司 | 2023-05-02 | — | — | CN | claimed |
| EP-2849776-A2 | GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE TREATMENT OF DIABETES | TransTech Pharma, LLC (US) | 2015-03-25 | — | — | EP | claimed |
| WO-2014137797-A2 | STABLE GLUCOKINASE ACTIVATOR COMPOSITIONS | TRANSTECH PHARMA, LLC (US) | 2014-09-12 | — | — | WO | claimed |
| US-20140066372-A1 | Glucokinase Activator Compositions for the Treatment of Diabetes | TRANSTECH PHARMA, LLC (US) | 2014-03-06 | — | — | US | claimed |
| WO-2013173417-A2 | GLUCOKINASE ACTIVATOR COMPOSITIONS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2013-11-21 | — | — | WO | claimed |
| EP-1723128-B1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2012-11-07 | — | — | EP | claimed |
| US-8263634-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2012-09-11 | — | — | US | claimed |
| US-20110313007-A1 | USE OF METFORMIN IN COMBINATION WITH A GLUCOKINASE ACTIVATOR AND COMPOSITIONS COMPRISING METFORMIN AND A GLUCOKINASE ACTIVATOR | TRANSTECH PHARMA, INC. (US) | 2011-12-22 | — | — | US | claimed |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-03-10 | — | — | US | claimed |
| US-7851636-B2 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | NOVO NORDISK A/S (DK) | 2010-12-14 | — | — | US | claimed |
| US-20100204288-A1 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | NOVO NORDISK A/S (DK) | 2010-08-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479808-B2 | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof | UTS2R, REN, UMPS | CCNE1 4578/4885CDK2 1765/4885CCNE2 4545/4885 |
| US-20230219910-A1 | CRYSTALLINE FORMS OF {2-[3-CYCLOHEXYL-3-(TRANS-4-PROPOXY-CYCLOHEXYL)-UREIDO]-THIAZOL-5-YLSULFANYL}-ACETIC ACID AND USES THEREOF | UACA, IAPP, SLC5A2 | CCNE1 2695/4885CDK2 1204/4885CCNE2 2416/4885 |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | GCK, HK1, HK2 | CCNE1 2830/4885CDK2 547/4885CCNE2 2532/4885 |
| US-20230219909-A1 | SALTS OR CO-CRYSTALS OF {2-[3-CYCLOHEXYL-3-(TRANS-4-PROPOXY-CYCLOHEXYL)-UREIDO]-THIAZOL-5-YLSULFANYL}-ACETIC ACID AND USES THEREOF | UTS2R, REN, PKD1 | CCNE1 4538/4885CDK2 1759/4885CCNE2 4558/4885 |
| US-20100204288-A1 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | GCK, GCKR, HK1 | CCNE1 4422/4885CDK2 1775/4885CCNE2 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.